Published in Br J Cancer on August 01, 1998
Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res (2009) 1.14
Duodenal carcinoma at the ligament of Treitz. A molecular and clinical perspective. BMC Gastroenterol (2010) 1.09
Small bowel adenocarcinomas--existing evidence and evolving paradigms. Nat Rev Clin Oncol (2013) 0.99
Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist (2012) 0.92
Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine. Gastric Cancer (2009) 0.89
Chemotherapy for small-bowel Adenocarcinoma at a single institution. Surg Today (2009) 0.88
Blood loss anemia due to adenocarcinoma of the jejunum: case report and review of the literature. Cases J (2009) 0.83
Small bowel adenocarcinoma presenting with refractory iron deficiency anemia - case report and review of literature. Case Rep Oncol (2011) 0.83
Adenocarcinoma of the small bowel: a surgical dilemma. Saudi J Gastroenterol (2009) 0.82
Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. BMC Cancer (2011) 0.82
Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience. BMC Cancer (2015) 0.80
Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol (2009) 0.80
A Patient With Metastatic Adenocarcinoma of the Jejunum Who Had a Prolonged Complete Response to FOLFOX. Gastrointest Cancer Res (2012) 0.75
Adenocarcinoma of Small Bowel. Rare Tumors (2015) 0.75
A Retrospective Review of Chemotherapy for Patients with Small Bowel Adenocarcinoma in British Columbia. J Cancer (2016) 0.75
Most small bowel cancers are revealed by a complication. Einstein (Sao Paulo) (2015) 0.75
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. Int J Clin Oncol (2017) 0.75
Reporting results of cancer treatment. Cancer (1981) 28.83
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer (1993) 1.69
Adenocarcinoma of the small intestine. Am J Surg (1984) 1.51
Carcinoma of the duodenum: comparison of surgery, radiotherapy, and chemotherapy. Br J Surg (1973) 1.34
Improving resectability and survival in patients with primary duodenal carcinoma. Am J Surg (1993) 1.26
Chemotherapy for primary adenocarcinoma of the small bowel. Cancer (1984) 1.20
Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys (1994) 1.05
Adenocarcinoma of the duodenum: factors influencing survival. French Association for Surgical Research. Br J Surg (1994) 1.02
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Cancer (1996) 0.98
Primary adenocarcinoma of duodenal bulb benefitted by chemotherapy. Dig Dis Sci (1991) 0.90
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med (1996) 7.06
Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid. Nature (2008) 6.16
On the Interpretation of Multi-Hit Survival Curves. Proc Natl Acad Sci U S A (1949) 5.96
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Insulin biosynthesis: evidence for a precursor. Science (1967) 5.05
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet (2001) 5.01
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med (1990) 4.10
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Biotechnology awareness study, Part 1: Where scientists get their information. Bull Med Libr Assoc (1991) 3.85
Three cdg operons control cellular turnover of cyclic di-GMP in Acetobacter xylinum: genetic organization and occurrence of conserved domains in isoenzymes. J Bacteriol (1998) 3.81
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res (2000) 3.41
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer (1998) 3.36
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol (2009) 3.33
Effect of reactive pharmacy intervention on quality of hospital prescribing. BMJ (1990) 3.25
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med (1993) 3.23
Heterogeneity of microsatellite mutations within and between loci, and implications for human demographic histories. Genetics (1998) 3.12
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
Genetic manipulation of centromere function. Mol Cell Biol (1987) 2.97
Equatorius: a new hominoid genus from the Middle Miocene of Kenya. Science (1999) 2.92
The effect of hand dominance on recurrent idiopathic paediatric epistaxis. Clin Otolaryngol (2008) 2.83
Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(®)) Society recommendations. World J Surg (2013) 2.77
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol (1997) 2.71
A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. Clin Chim Acta (1975) 2.64
Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension (2000) 2.55
Failure of early diagnosis in symptomatic Duchenne muscular dystrophy. Lancet (1999) 2.49
Radiographic interpretation by nurse practitioners in a minor injuries unit. J Accid Emerg Med (1996) 2.44
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol (2005) 2.41
Validation of the Arizona Activity Frequency Questionnaire using doubly labeled water. Med Sci Sports Exerc (2001) 2.40
The use of out of hours health services: a cross sectional survey. BMJ (1998) 2.36
Bile acid transformations by microbial strains belonging to genera found in intestinal contents. Acta Pathol Microbiol Scand (1967) 2.33
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Perinatal hypoxic-ischemic thalamic injury: clinical features and neuroimaging. Ann Neurol (1998) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr (2012) 2.25
From quantity to quality: the central cardiac audit database project. Heart (1999) 2.23
Chromatin conformation of yeast centromeres. J Cell Biol (1984) 2.19
Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet (1995) 2.17
Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events. J Virol (2001) 2.13
Management of carcinomas of the upper gastrointestinal tract. BMJ (1994) 2.12
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 2.12
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer (1996) 2.11
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol (1996) 2.08
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol (1995) 2.08
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
Detection of ambulatory ischaemia is not of practical clinical value in the routine management of patients with stable angina. A long-term follow-up study. Eur Heart J (1995) 1.97
Measles, mumps, and rubella vaccination. BMJ (1992) 1.96
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine (Baltimore) (1991) 1.89
Polypeptide composition of bacterial cyclic diguanylic acid-dependent cellulose synthase and the occurrence of immunologically crossreacting proteins in higher plants. Proc Natl Acad Sci U S A (1991) 1.89
Magnetic resonance imaging volumes of the hippocampus and the amygdala in women with borderline personality disorder and early traumatization. Arch Gen Psychiatry (2000) 1.88
Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther (1997) 1.86
Reproducibility of measurements of oestrogen-receptor concentration in breast cancer. Br J Cancer (1977) 1.85
Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med (Berl) (1998) 1.83
The milk-ejection reflex of the rat: an intermittent function not abolished by surgical levels of anaesthesia. J Endocrinol (1973) 1.82
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer (2005) 1.81
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80
Proliferation of human lymphocytes in culture. Nature (1966) 1.76
A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol) (2007) 1.75
The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol Alcohol (2001) 1.69
HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. BMJ (1995) 1.69
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.68
A test for the practical evaluation of male fertility by acridine orange (AO) fluorescence. Fertil Steril (1984) 1.68
FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer (2000) 1.68
MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer (2006) 1.68
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer (2002) 1.66
Weight history, glucose intolerance, and insulin levels in middle-aged Swedish men. Am J Epidemiol (1998) 1.66
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol (2012) 1.65
Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology (1997) 1.62
Renal artery stent revascularization with embolic protection in patients with ischemic nephropathy. Kidney Int (2006) 1.61
A genetic register for von Hippel-Lindau disease. J Med Genet (1996) 1.61
Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut (2003) 1.61
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol (1999) 1.59
Changing disease patterns in AIDS. BMJ (1991) 1.59
Thalamic hemorrhage with intraventricular hemorrhage in the full-term newborn. Pediatrics (1990) 1.59
Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer (2007) 1.58
Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. Mol Psychiatry (2009) 1.57
Rapid destructive osteoarthritis: clinical, radiographic, and pathologic features. Radiology (1992) 1.56
The mutational spectrum in Waardenburg syndrome. Hum Mol Genet (1995) 1.55